These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

528 related items for PubMed ID: 24348242

  • 1. The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.
    VanBlargan LA, Mukherjee S, Dowd KA, Durbin AP, Whitehead SS, Pierson TC.
    PLoS Pathog; 2013; 9(12):e1003761. PubMed ID: 24348242
    [Abstract] [Full Text] [Related]

  • 2. Dengue Virus Serotype 1 Conformational Dynamics Confers Virus Strain-Dependent Patterns of Neutralization by Polyclonal Sera.
    VanBlargan LA, Milutinovic PS, Goo L, DeMaso CR, Durbin AP, Whitehead SS, Pierson TC, Dowd KA.
    J Virol; 2021 Nov 09; 95(23):e0095621. PubMed ID: 34549976
    [Abstract] [Full Text] [Related]

  • 3. Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes.
    Gallichotte EN, Baric TJ, Yount BL, Widman DG, Durbin A, Whitehead S, Baric RS, de Silva AM.
    PLoS Pathog; 2018 Feb 09; 14(2):e1006934. PubMed ID: 29481552
    [Abstract] [Full Text] [Related]

  • 4. A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses.
    Wollner CJ, Richner M, Hassert MA, Pinto AK, Brien JD, Richner JM.
    J Virol; 2021 May 24; 95(12):. PubMed ID: 33762420
    [Abstract] [Full Text] [Related]

  • 5. Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.
    Thomas A, Thiono DJ, Kudlacek ST, Forsberg J, Premkumar L, Tian S, Kuhlman B, de Silva AM, Metz SW.
    J Virol; 2020 Aug 31; 94(18):. PubMed ID: 32611757
    [Abstract] [Full Text] [Related]

  • 6. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies.
    Poddar A, Ramasamy V, Shukla R, Rajpoot RK, Arora U, Jain SK, Swaminathan S, Khanna N.
    BMC Biotechnol; 2016 Jun 14; 16(1):50. PubMed ID: 27301568
    [Abstract] [Full Text] [Related]

  • 7. Beyond Neutralizing Antibody Levels: The Epitope Specificity of Antibodies Induced by National Institutes of Health Monovalent Dengue Virus Vaccines.
    Swanstrom JA, Nivarthi UK, Patel B, Delacruz MJ, Yount B, Widman DG, Durbin AP, Whitehead SS, De Silva AM, Baric RS.
    J Infect Dis; 2019 Jun 19; 220(2):219-227. PubMed ID: 30895307
    [Abstract] [Full Text] [Related]

  • 8. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design.
    Li XQ, Qiu LW, Chen Y, Wen K, Cai JP, Chen J, Pan YX, Li J, Hu DM, Huang YF, Liu LD, Ding XX, Guo YH, Che XY.
    J Gen Virol; 2013 Oct 19; 94(Pt 10):2191-2201. PubMed ID: 23851440
    [Abstract] [Full Text] [Related]

  • 9. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
    Tsai WY, Durbin A, Tsai JJ, Hsieh SC, Whitehead S, Wang WK.
    J Virol; 2015 Jul 19; 89(14):7348-62. PubMed ID: 25972550
    [Abstract] [Full Text] [Related]

  • 10. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A, Ngwe Tun MM, Moi ML, Sakurai A, Ishikawa M, Kuno S, Ueno R, Morita K, Akahata W.
    J Virol; 2017 Dec 01; 91(23):. PubMed ID: 28956764
    [Abstract] [Full Text] [Related]

  • 11. Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine.
    Tsai WY, Chen HL, Tsai JJ, Dejnirattisai W, Jumnainsong A, Mongkolsapaya J, Screaton G, Crowe JE, Wang WK.
    J Virol; 2018 Dec 01; 92(23):. PubMed ID: 30185598
    [Abstract] [Full Text] [Related]

  • 12. Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes.
    Uno N, Ross TM.
    J Virol; 2021 Jan 28; 95(4):. PubMed ID: 33208445
    [Abstract] [Full Text] [Related]

  • 13. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
    Nivarthi UK, Kose N, Sapparapu G, Widman D, Gallichotte E, Pfaff JM, Doranz BJ, Weiskopf D, Sette A, Durbin AP, Whitehead SS, Baric R, Crowe JE, de Silva AM.
    J Virol; 2017 Mar 01; 91(5):. PubMed ID: 28031369
    [Abstract] [Full Text] [Related]

  • 14. A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies.
    Gallichotte EN, Widman DG, Yount BL, Wahala WM, Durbin A, Whitehead S, Sariol CA, Crowe JE, de Silva AM, Baric RS.
    mBio; 2015 Oct 13; 6(5):e01461-15. PubMed ID: 26463165
    [Abstract] [Full Text] [Related]

  • 15. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
    Frei JC, Wirchnianski AS, Govero J, Vergnolle O, Dowd KA, Pierson TC, Kielian M, Girvin ME, Diamond MS, Lai JR.
    J Virol; 2018 Sep 15; 92(18):. PubMed ID: 29976679
    [Abstract] [Full Text] [Related]

  • 16. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y, Zhou J, Yu Z, Fang D, Fu C, Zhu X, He Z, Yan H, Jiang L.
    BMC Microbiol; 2014 Dec 18; 14():233. PubMed ID: 25520151
    [Abstract] [Full Text] [Related]

  • 17. Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1.
    Messer WB, Yount BL, Royal SR, de Alwis R, Widman DG, Smith SA, Crowe JE, Pfaff JM, Kahle KM, Doranz BJ, Ibarra KD, Harris E, de Silva AM, Baric RS.
    J Virol; 2016 May 15; 90(10):5090-5097. PubMed ID: 26962223
    [Abstract] [Full Text] [Related]

  • 18. Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine.
    Galula JU, Shen WF, Chuang ST, Chang GJ, Chao DY.
    J Virol; 2014 Sep 15; 88(18):10813-30. PubMed ID: 25008922
    [Abstract] [Full Text] [Related]

  • 19. Characterization of the Type-Specific and Cross-Reactive B-Cell Responses Elicited by a Live-Attenuated Tetravalent Dengue Vaccine.
    Michlmayr D, Andrade P, Nascimento EJM, Parker A, Narvekar P, Dean HJ, Harris E.
    J Infect Dis; 2021 Feb 03; 223(2):247-257. PubMed ID: 32572472
    [Abstract] [Full Text] [Related]

  • 20. Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes.
    Andrade DV, Katzelnick LC, Widman DG, Balmaseda A, de Silva AM, Baric RS, Harris E.
    mBio; 2017 Sep 19; 8(5):. PubMed ID: 28928210
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.